top of page
Search
BULGAR

Generic version ng antiviral COVID-19 pill na Paxlovid, aprubado na ng FDA

ni Jasmin Joy Evangelista | January 11, 2022



Inaprubahan na ng Philippine Food and Drug Administration (FDA) ang generic version ng antiviral COVID-19 pill ng Pfizer na Paxlovid, ayon kay FDA Director Oscar Gutierrez Jr. sa taped briefing kasama si Pangulong Rodrigo Duterte.


“The FDA has approved the application of the DOH [Department of Health] for a compassionate special permit institutional use to make accessible the first generic version of Paxlovid with the brand name Bexovid,” ani Gutierrez.


“It is hoped that the cost of treatment would be cheaper because Bexovid is a generic drug,” dagdag niya.


Ayon kay Gutierrez, ang Bexovid ang kauna-unahang generic counterpart ng Pfizer’s Paxlovid.


Ang treatment ay ibibigay sa dalawang tablets — isang Nirmatelvir at isang Ritonavir — iinumin nang sabay, dalawang beses isang araw sa loob ng limang araw.


“It’s indicated for those age 12 or older who have a mild to moderate infection,” ani Gutierrez.


Batay sa datos ng Pfizer, sinabi rin ni Gutierrez na nababawasan ng 89% ang posibilidad na maospital o mamatay ang isang Covid patient kung iinom ng Bexovid sa loob ng tatlong araw na nakararanas ng mga sintomas — at 88% sa loob ng limang araw.


“This helps to prevent hospitals from overcrowding and overwhelming healthcare workers,” aniya.


Sa sandaling ma-deliver na ng Biocare Lifescience Inc. ang mga gamot, magiging available na ito sa mga government hospitals.


“It’s up to the DOH to determine how this will be made available to the patients,” pahayag pa ni Gutierrez.


Samantala, patuloy na nakikipag-ugnayan ang gobyerno sa Pfizer hinggil sa emergency use authorization (EUA) ng Paxlovid antiviral drug.

0 comments

Recent Posts

See All

Comments


Disclaimer : The views and opinions expressed on this website or any comments found on any articles herein, are those of the authors or columnists alike, and do not necessarily reflect nor represent the views and opinions of the owner, the company, the management and the website.

RECOMMENDED
bottom of page